A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.

ovartis Pharma Services AG0 sites5,000 target enrollmentOctober 13, 2010

Conditionsmultiple sclerosis MedDRA version: 18.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disorders Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: multiple sclerosis
Sponsor: ovartis Pharma Services AG
Enrollment: 5000
Status: Active, not recruiting
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

October 13, 2010

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

ovartis Pharma Services AG

Eligibility Criteria

Inclusion Criteria

•Patients eligible for inclusion in this study have to fulfill all of the following criteria:
•1\. Written informed consent must be obtained before any assessment is performed.
•2\. Patients who have completed designated ongoing or planned trials with fingolimod, including phase II/III patients who have already completed CFTY720D2399,CFTY720D2309/E1 or one of the phase II/III core or extension studies.
•3\. Patients who participated in any designated global fingolimod MS trial other than phase II/III (e.g. CFTY720D2316, CFTY720D2320, etc.) and are less than 180 days beyond the time of local approval and general reimbursement.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

•Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
•1\. Premature permanent discontinuation from any fingolimod study due to:
•a. An adverse event or serious adverse event or laboratory abnormality.
•b. Conditions leading to permanent study drug discontinuation.
•Patients who temporarily or permanently discontinued from any fingolimod study because of pregnancy can be re\-enrolled.
•2\. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/ml).
•3\. Women of child\-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are using highly effective contraception during the study and for 2 months after stopping treatment. ‘Highly effective contraception’defined as contraception which results in less than 1% unwanted pregnancies when used properly according to the label.
•Women are considered post\-menopausal and not of child\-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to baseline. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
•4\. Chronic disease of the immune system other than MS which may require immunosuppressive treatment.
•5\. Severe active infection or active chronic infection.